A recently presented follow-up study reported robust and sustained clinical responses to crizotinib therapy in pediatric patients with ALCL and IMT, stressing the importance of abrogating ALK kinase activity in these diseases27. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.